Access Vascular Secures Financing to Support FDA Application for HydroPICC Device

 

August 28, 2017—Access Vascular, which develops venous access devices designed to eliminate thrombotic risk, announced $3.7 million in funding to support the submission of a 510(k) application to the US Food and Drug Administration for the company's lead product, the HydroPICC peripherally inserted central catheter, later this year. The HydroPICC device uses the company's bulk hydrophilic biomaterial platform that is designed to significantly reduce the accumulation of platelets and lower the risk of thrombosis. The funding comes from individual investors and angelMD, an investment platform and marketplace connecting innovative medical startups, physicians, investors, and industry partners.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.